Developing improvements in cannabidiol and other cannabinoids from C. sativa, and a computational analysis of the interaction between the cannabinoids and relevant receptors

随着大麻在加拿大合法化，我们预计公开娱乐用途将会增加。然而，**THC，这种具有精神活性的大麻素是已知的仅有的113种由花椰菜生产的大麻素之一。初步研究表明，其他大麻素虽然缺乏任何精神活性，但可能具有潜在的生物医学应用，包括抗癌、消炎和局部止痛**活性。它们可以为从现成的**材料开发新的治疗类别提供一个起点。然而，在我们能够推进这一领域之前，必须解决几个问题。我们需要一种易于**扩展、简单和廉价的方法来从植物粗提物中分离高纯度和高产量的大麻二酚(CBD)。我们还需要更好地了解CBD和其他次要大麻素与细胞表面各种受体的亲和力，因为这些相互作用的轮廓决定了生理效应。温莎大学和医用大麻的主要种植者Aphria之间的这项**合作旨在**解决这两个问题。

With the legalization of cannabis in Canada, we expect to see an increase in overt recreational use. However,**THC, the psychoactive cannabinoid is one of only 113 known cannabinoids produced by C. sativa. Preliminary**research has shown that the other cannabinoids, although lacking any psychoactive activity, might have**potentially potent biomedical applications, including for anti-cancer, anti-inflammatory, and local analgesic**activity. They could provide a starting point for developing new classes of therapies from readily available**materials. However, several problems must be addressed before we can advance the field. We need an easily**scalable, simple, and inexpensive method to isolate cannabidiol (CBD) from crude plant extracts in high purity**and yield. We also need an improved understanding of the affinity of CBD and other minor cannabinoids for the**various receptors on cell surfaces as the profile of these interactions determines the physiological effects. This**collaboration between the University of Windsor and Aphria, a leading grower of medical cannabis, seeks to**address both of these issues.